Security Snapshot

Autolus Therapeutics plc - ADSs, each representing one ordinary share, nominal value $0.000042 per share, and ordinary shares, nominal value $0.000042 per share (AUTL) Institutional Ownership

CUSIP: 05280R100

13F Institutional Holders and Ownership History from Q2 2018 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

83

Shares (Excl. Options)

132.2MFull value: 132,203,060 · shares · 30 Jun 2026

Price

$1.60

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / ADSs, each representing one ordinary share, nominal value $0.000042 per share, and ordinary shares, nominal value $0.000042 per share
Symbol
AUTL on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
132,203,060
Latest holder snapshot 5 signals
Total 13F value
$211,968,383
Portfolio coverage rank
0%
Share change
-2,254,126
Value change
-$3,549,993
Number of holders
83
Issuer context Names, identifiers, and filing context for this profile. 2 identity fields
Shares outstanding
263,969,196
SEC-reported price per share
$1.94
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • AUTL - Autolus Therapeutics plc - ADSs, each representing one ordinary share, nominal value $0.000042 per share, and ordinary shares, nominal value $0.000042 per share is tracked under CUSIP 05280R100.
  • 83 institutions reported positions in Q2 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 84 to 83 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $184.35MFull value: $184,354,727 · USD · 31 Mar 2026
    to
    $211.97MFull value: $211,968,383 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 83 institutions filings for Q2 2026.

Open SEC evidence

Security key

05280R100

13F reference period

Q2 2026

13F holders

83

13D/G owners

6

CIK / CUSIP context first

Open Q2 2026 holders AUTL full holder history Autolus Therapeutics plc SEC filings Autolus Therapeutics plc company facts Autolus Therapeutics plc insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
AUTL
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
MAK Capital Fund LP 13% +12% $49,423,586 +$5,315,732 33,621,487 +12% MAK Capital Fund LP 31 Mar 2026
Syncona Portfolio Ltd 11% $37,755,579 28,821,053 Syncona Portfolio Limited 31 Mar 2025
ARMISTICE CAPITAL, LLC 5.6% -5% $22,200,000 -$1,184,000 15,000,000 -5.1% Armistice Capital, LLC 30 Jun 2026
PPF Group a.s. 5.6% $22,616,881 14,782,275 PPF Group a.s. 27 Aug 2026
FMR LLC 3.8% $13,312,676 10,162,348 FMR LLC 31 Mar 2025
Deep Track Capital, LP 0.97% $4,186,839 2,568,613 Deep Track Capital, LP 30 Sep 2025
As of 30 Jun 2026, 83 institutional investors reported holding
132.2MFull value: 132,203,060 · shares · 30 Jun 2026
shares of Autolus Therapeutics plc - ADSs, each representing one ordinary share, nominal value $0.000042 per share, and ordinary shares, nominal value $0.000042 per share (AUTL). This represents 50% of the company’s total
263.97MFull value: 263,969,196 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
49%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
MAK CAPITAL ONE LLC 13% 33,621,487 0% 7.5% $53,794,379
Blackstone Inc. 7.8% 20,485,611 0% 0.09% $32,776,978
Syncona Portfolio Ltd 6.3% 16,640,720 0% 100% $26,625,152
ARMISTICE CAPITAL, LLC 5.7% 15,000,000 -5.1% 0.66% $24,000,000
Tetragon Partners GP Ltd 3.6% 9,500,000 0% 2.5% $15,200,000
SCHRODER INVESTMENT MANAGEMENT GROUP 3% 7,833,282 -17% 0.01% $12,924,915
Frazier Life Sciences Management, L.P. 1.7% 4,447,910 0% 0.15% $7,116,656
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.3% 3,361,156 0% 0.01% $5,377,850
Laurion Capital Management LP 1.3% 3,316,626 0% 0.38% $5,306,602
RENAISSANCE TECHNOLOGIES LLC 0.75% 1,984,700 -14% 0% $3,175,520
BANK OF AMERICA CORP /DE/ 0.61% 1,605,092 -13% 0% $2,568,147
BlackRock, Inc. 0.61% 1,603,458 +8.3% 0% $2,565,532
UBS Group AG 0.57% 1,516,991 +16% 0% $2,427,186
MORGAN STANLEY 0.48% 1,260,832 +34% 0% $2,017,331
MILLENNIUM MANAGEMENT LLC 0.46% 1,224,818 +498% 0% $1,959,709
Cetera Investment Advisers 0.44% 1,157,324 +2.5% 0% $1,851,718
Balyasny Asset Management L.P. 0.37% 972,748 +0.11% 0% $1,556,397
JPMORGAN CHASE & CO 0.35% 913,239 -2.4% 0% $1,506,844
Alphabet Inc. 0.26% 698,262 0% 0% $1,117,219
CITADEL ADVISORS LLC 0.26% 695,890 +51% 0% $1,113,424
Hennion & Walsh Asset Management, Inc. 0.17% 451,403 +2.5% 0.02% $722,245
Privium Fund Management B.V. 0.14% 363,430 0% 0.11% $581,488
EDENTREE ASSET MANAGEMENT Ltd 0.11% 300,000 0% 0.15% $477,000
JANE STREET GROUP, LLC 0.11% 299,862 +22% 0% $479,779
XTX Topco Ltd 0.11% 287,456 +410% 0.01% $459,930

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
34
Headline period
Q2 2026
Rows shown
1-25 of 34
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 21,138,534 $41,003,620 -$1,170,371 $1.94 21
2026 Q2 132,203,060 $211,968,383 -$3,549,993 $1.60 83
2026 Q1 134,436,091 $184,354,727 -$5,299,969 $1.38 84
2025 Q4 139,369,843 $277,117,628 -$1,857,316 $1.99 90
2025 Q3 143,579,673 $233,669,297 -$67,552,879 $1.63 95
2025 Q2 165,944,662 $378,376,899 +$9,844,394 $2.28 93
2025 Q1 168,007,060 $260,819,521 -$3,531,773 $1.55 93
2024 Q4 168,335,372 $395,090,875 -$37,054,930 $2.35 107
2024 Q3 178,602,235 $648,320,594 +$2,536,180 $3.63 97
2024 Q2 178,106,548 $619,765,055 -$54,511,638 $3.48 106
2024 Q1 175,580,707 $1,120,176,501 +$380,385,653 $6.38 114
2023 Q4 115,868,017 $746,230,557 +$30,259,044 $6.44 97
2023 Q3 110,707,409 $257,962,960 +$2,926,164 $2.33 67
2023 Q2 109,330,876 $260,181,467 +$12,434,850 $2.38 67
2023 Q1 105,962,470 $194,950,415 -$3,026,243 $1.84 64
2022 Q4 107,371,378 $203,976,112 +$109,842,474 $1.90 69
2022 Q3 49,366,337 $105,661,961 -$3,352,319 $2.14 62
2022 Q2 50,829,136 $143,849,865 -$7,115,566 $2.83 57
2022 Q1 45,661,103 $190,513,250 -$17,791,387 $4.17 60
2021 Q4 52,463,220 $272,271,730 +$101,855,863 $5.19 69
2021 Q3 25,076,258 $164,226,984 -$2,136,433 $6.55 55
2021 Q2 25,378,541 $169,575,110 +$23,313,452 $6.64 64
2021 Q1 22,400,702 $128,321,739 +$53,655,759 $5.73 58
2020 Q4 12,635,638 $112,960,120 +$962,285 $8.94 46
2020 Q3 12,386,365 $143,379,095 -$24,849,875 $11.64 44
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .